Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement regarding targeted cancer therapy. This innovative antibody-drug conjugate pairs a monoclonal antigen specifically focused on HER2 expressing cells with the potent chemotherapeutic payload, deruxtecan. The route of action involves the antibody's ability to conn